预约演示
更新于：2026-09-09
Dexamethasone Sodium Phosphate
地塞米松磷酸钠
更新于：2026-09-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1959-08-26) |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-FCJDYXGNSA-N |
CAS号2392-39-4 |
关联
3,132
项与 地塞米松磷酸钠 相关的临床试验NCT07605416
Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial
NCT07791264
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
NCT07097493
Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canal and iPACK Blocks in Patients Undergoing Primary Total Knee Arthroplasty
100 项与 地塞米松磷酸钠 相关的临床结果
登录后查看更多信息
100 项与 地塞米松磷酸钠 相关的转化医学
登录后查看更多信息
100 项与 地塞米松磷酸钠 相关的专利（医药）
登录后查看更多信息
1,507
项与 地塞米松磷酸钠 相关的文献（医药）2026-10-01Topics in Companion Animal Medicine
Concurrent Babesia gibsoni infection as a negative prognostics indicator of survival in dogs diagnosed with immune-mediated hemolytic anemia: A prospective cohort study
Article
作者: Atapattu, Ushani ; Ariyarathna, Harsha ; Jinadasa, Rasika ; Dissanayake, Anuruddhika ; Govinna, Mihidum ; Bandaranayaka, Nishadi ; Satharasinghe, Dilan
Immune-mediated haemolytic anaemia (IMHA) is a common autoimmune disorder in dogs. Haemoparasites, particularly intracellular organisms, are well-recognized causes of secondary IMHA and are associated with poorer clinical outcomes. However, the prognostic impact of concurrent Babesia gibsoni infection in dogs with IMHA remains incompletely characterized. This study aimed to compare survival outcomes between dogs with primary IMHA and those with IMHA associated with B. gibsoni infection. Fifty-five dogs (34 purebred, 21 crossbred; age 7 months-9 years) diagnosed with IMHA, according to ACVIM guidelines, were included. Twenty-six dogs had primary IMHA (11 males, 15 females), and 29 dogs had IMHA with natural B. gibsoni infection (12 males, 17 females), confirmed by PCR. All dogs received immunosuppressive therapy consisting of prednisolone (1 mg/kg q12h PO) or dexamethasone sodium phosphate (0.2 mg/kg q24h IV). Dogs with B. gibsoni infection additionally received antibabesial treatment that included initial imidocarb dipropionate (6.6 mg/kg IM) in two weeks interval, and doxycycline up to three weeks (10 mg/kg q12h PO). Cases were followed for 60 days. Survival analysis was performed using Cox proportional hazards regression. During follow-up, 40 dogs died of IMHA and 2 from unrelated causes. In multivariable analysis, male sex (HR=2.1; 95% CI: 1.1-4.2; p=0.034), marked spherocytosis (HR=2.1; 95% CI: 1.1-4.3; p=0.032), and concurrent B. gibsoni infection (HR=2.6; 95% CI: 1.2-2.9; p=0.024) were independently associated with increased hazard of death. In conclusion, male sex, marked spherocytosis, and B. gibsoni co-infection are key independent predictors of a poor prognosis in dogs with IMHA.
2026-07-01EUROPEAN JOURNAL OF NEUROLOGY
Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia‐Telangiectasia: A Systematic Review
Review
作者: Pisani, Francesco ; Spagnoli, Carlotta ; Paparella, Roberto ; Leuzzi, Vincenzo ; Urciuolo, Giorgia ; Panvino, Fabiola ; Galosi, Serena
ABSTRACT:
Introduction:
Ataxia‐telangiectasia (AT) is characterized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency, and increased cancer susceptibility. No disease‐modifying treatment is available. This systematic review aimed to evaluate the efficacy and safety of pharmacological interventions for ataxia in pediatric AT.
Method:
A systematic search was conducted across MEDLINE, Scopus, Web of Science, and
ClinicalTrials.gov
through December 2025. Eligible studies included randomized controlled trials (RCTs) and single‐arm interventional studies evaluating pharmacological treatments for cerebellar ataxia in patients aged ≤ 18 years with genetically confirmed AT.
Results:
Thirteen studies (3 RCTs, 10 single‐arm trials) involving 314 participants (mean age 10.87 years) were included. Interventions included betamethasone, erythrocyte‐encapsulated dexamethasone (eDSP), nicotinamide riboside (NR), leucine derivatives, and amantadine. Betamethasone demonstrated transient improvements in the Scale for the Assessment and Rating of Ataxia (SARA) and International Cooperative Ataxia Rating Scale (ICARS) scores, with dose‐dependent systemic toxicity. eDSP showed favorable tolerability but was ineffective in phase 3 trials, although subgroup analyses suggested a potential benefit in children aged 6–9 years. NR supplementation improved SARA and AT Neurological Examination Scale Toolkit (AT‐NEST) scores in open‐label studies. Leucine derivatives showed mixed results. Amantadine showed benefits in patients with extrapyramidal symptoms.
Conclusions:
The recurrent pattern of promising open‐label findings followed by negative phase 3 results highlights a translational gap attributable to methodological limitations, including small sample sizes, heterogeneous populations, and variable outcome measures. The non‐linear disease progression and age‐dependent treatment response further complicate trial design. Current evidence remains insufficient to guide clinical practice.
Trial Registration:
PROSPERO number: CRD420251184721
2026-07-01VETERINARY ANAESTHESIA AND ANALGESIA
Novel ultrasound-guided flags assisted WalKing block for enhanced recovery after surgery (FAWKES) in three dogs undergoing tibial plateau levelling osteotomy
Article
作者: Le, Stephanie ; Gingold, Benjamin Mc ; Milloway, Matthew C
This case series describes a novel, regional anesthesia technique in three dogs of various breeds, aged 2.5, 8, and 10 years old, weighing 42.6, 32.6, and 13.4 kg, respectively, presenting for tibial plateau levelling osteotomy. Physical examination was unremarkable aside from evidence of a ruptured cranial cruciate ligament. After anesthetic premedication and induction of general anesthesia, the affected limb was aseptically prepared. A combination of regional nerve blocks was performed, including the inFiLtrating Around Genicular Structures (FLAGS) block, saphenous block, and periarticular knee infiltration; together, termed the Flags Assisted WalKing block for Enhanced recovery after Surgery (FAWKES). A mixture of 0.5% ropivacaine (4 mg kg-1), dexmedetomidine (1.6 ug kg-1), dexamethasone sodium phosphate (0.004 mg kg-1), and epinephrine (4 ug kg-1) was used for the FLAGS (0.2 mL kg-1), saphenous (0.1 mL kg-1), and periarticular knee infiltration (0.125 mL kg-1 per site; four sites). There were no increases in heart rate, respiratory rate, or mean arterial blood pressure greater than 20% from surgical start time to end time, aside from expected elevations following administration of anticholinergics or vasopressors. All dogs retained motor function postoperatively. Two of the three dogs ambulated on the operated limb within one hour of recovery. The third was nonweight-bearing but able to flex the stifle and elevate the limb. One dog was given a single postoperative dose of intravenous methadone (0.2 mg kg-1) 12 hours after surgery, whereas the remaining dogs required no rescue analgesia. All dogs ate within 12 hours of surgery and were discharged without complications. These findings suggest that the described multimodal analgesic plan, including the FAWKES block, provided adequate intraoperative analgesia while preserving motor function postoperatively. Controlled studies are required to evaluate the efficacy and safety of the FAWKES block, along with more detailed anatomical investigations of the canine stifle joint.
630
项与 地塞米松磷酸钠 相关的新闻（医药）2026-09-08
申请上市抗体药物偶联物ASH会议
2026-09-06
优先审批临床研究临床结果上市批准
100 项与 地塞米松磷酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑水肿 | 奥地利 | 2021-04-28 | |
| 脑水肿 | 比利时 | 2021-04-28 | |
| 脑水肿 | 保加利亚 | 2021-04-28 | |
| 脑水肿 | 克罗地亚 | 2021-04-28 | |
| 脑水肿 | 捷克 | 2021-04-28 | |
| 脑水肿 | 丹麦 | 2021-04-28 | |
| 脑水肿 | 芬兰 | 2021-04-28 | |
| 脑水肿 | 德国 | 2021-04-28 | |
| 脑水肿 | 匈牙利 | 2021-04-28 | |
| 脑水肿 | 冰岛 | 2021-04-28 | |
| 脑水肿 | 爱尔兰 | 2021-04-28 | |
| 脑水肿 | 意大利 | 2021-04-28 | |
| 脑水肿 | 荷兰 | 2021-04-28 | |
| 脑水肿 | 挪威 | 2021-04-28 | |
| 脑水肿 | 波兰 | 2021-04-28 | |
| 脑水肿 | 葡萄牙 | 2021-04-28 | |
| 脑水肿 | 罗马尼亚 | 2021-04-28 | |
| 脑水肿 | 斯洛伐克 | 2021-04-28 | |
| 脑水肿 | 斯洛文尼亚 | 2021-04-28 | |
| 新型冠状病毒感染 | 奥地利 | 2021-04-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 美国 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 美国 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 澳大利亚 | 2019-11-26 | |
| 膝关节炎 | 临床3期 | 澳大利亚 | 2019-11-26 | |
| 根性疼痛 | 临床3期 | 美国 | 2017-12-08 | |
| 神经根病 | 临床3期 | 美国 | 2017-12-08 | |
| 共济失调毛细血管扩张 | 临床3期 | 美国 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 澳大利亚 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 比利时 | 2017-03-02 | |
| 共济失调毛细血管扩张 | 临床3期 | 德国 | 2017-03-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 438 | (Group 1) | 顧顧築齋築醖網鹹衊艱(襯繭簾憲顧窪遞憲衊窪) = 製築壓鹽選選襯蓋獵鏇 鬱願鑰鹽憲繭鹽選繭襯 (願鏇遞選醖鹹鬱鹹範糧, 168.9) 更多 | - | 2026-08-03 | |
顧顧築齋築醖網鹹衊艱(襯繭簾憲顧窪遞憲衊窪) = 鏇襯繭糧網窪壓鬱觸獵 鬱願鑰鹽憲繭鹽選繭襯 (願鏇遞選醖鹹鬱鹹範糧, 122.3) 更多 | |||||||
临床4期 | 126 | (IV Dexmethsone and Oral Placebo) | 積鹽鏇壓顧鑰衊壓網鹹 = 網糧餘夢艱鏇襯餘簾膚 艱蓋壓齋觸積獵淵鬱築 (繭觸築蓋構膚願餘築淵, 獵製願願鏇繭齋願獵獵 ~ 衊積艱衊願蓋獵糧顧積) 更多 | - | 2026-07-29 | ||
(Oral Dexamethasone and IV Placebo) | 積鹽鏇壓顧鑰衊壓網鹹 = 衊壓壓願蓋遞餘齋齋膚 艱蓋壓齋觸積獵淵鬱築 (繭觸築蓋構膚願餘築淵, 範範範衊積糧鹹糧鏇衊 ~ 積築鏇願蓋齋範網鹽願) 更多 | ||||||
临床4期 | - | 209 | Oral dexamethasone | 鹽鹹齋遞網築範繭網遞(鏇襯餘鏇膚糧積遞鏇蓋) = 鬱築製淵襯夢餘衊蓋壓 網廠糧壓憲鹽積鏇夢獵 (餘積糧餘壓膚顧淵鏇製, 0 ~ 1.44) | 积极 | 2026-07-23 | |
Placebo | 鹽鹹齋遞網築範繭網遞(鏇襯餘鏇膚糧積遞鏇蓋) = 鑰蓋鬱構網觸繭願製餘 網廠糧壓憲鹽積鏇夢獵 (餘積糧餘壓膚顧淵鏇製, 2.15) | ||||||
临床2期 | 56 | (No Prior Chemo or Responded/Stable With Prior Chemo) | 襯築艱淵顧夢膚衊窪顧 = 構顧範鏇觸獵遞夢餘選 顧醖蓋齋憲簾壓壓遞鬱 (醖製積壓淵願窪醖蓋獵, 範襯憲艱壓選鹽鏇製鹽 ~ 鬱鑰憲膚鏇鬱衊餘遞淵) 更多 | - | 2026-07-01 | ||
(Patients Who Have Failed Systemic Therapy) | 築鏇夢壓願獵鬱糧衊製 = 獵鏇製艱鏇選鏇積鬱餘 醖夢衊築餘襯築觸鑰夢 (糧築積觸艱夢膚蓋膚夢, 顧範構艱遞夢遞膚夢鹽 ~ 築願衊構糧觸艱鏇餘積) 更多 | ||||||
临床2期 | 5 | 餘網獵艱糧憲淵夢蓋範 = 壓艱淵窪製齋艱鹽構壓 壓憲鏇衊繭糧願構簾鑰 (鬱夢觸壓製獵構鑰選窪, 築醖窪襯醖襯襯鹽淵艱 ~ 簾糧繭襯壓憲構廠齋淵) 更多 | - | 2026-06-25 | |||
临床4期 | 120 | (Anesthetic Without Steroid Group) | 積餘襯鏇顧繭衊壓壓糧(襯壓憲襯窪窪鏇遞壓齋) = 襯積餘蓋製鑰膚蓋餘廠 願選艱鹽鑰製製範鏇範 (淵醖壓憲齋遞製夢顧餘, 2.2) 更多 | - | 2026-06-24 | ||
(Anesthetic With Dexamethasone Group) | 積餘襯鏇顧繭衊壓壓糧(襯壓憲襯窪窪鏇遞壓齋) = 齋獵餘窪壓鑰觸願選衊 願選艱鹽鑰製製範鏇範 (淵醖壓憲齋遞製夢顧餘, 2.3) 更多 | ||||||
临床3期 | 90 | (Conventional) | 窪構繭願構糧廠壓壓襯 = 鹹壓簾獵餘鹽積淵蓋鬱 艱鹹鑰獵襯餘鹹製壓窪 (艱鑰範窪鏇顧蓋鏇膚齋, 鑰襯網齋淵網簾壓鹹製 ~ 鹽製顧築鹹鹽蓋獵衊網) 更多 | - | 2026-06-09 | ||
(Short-Course) | 窪構繭願構糧廠壓壓襯 = 構鑰壓糧構齋憲夢齋糧 艱鹹鑰獵襯餘鹹製壓窪 (艱鑰範窪鏇顧蓋鏇膚齋, 簾壓鬱鹹獵淵艱憲醖鏇 ~ 憲顧遞壓夢遞衊鹹繭餘) 更多 | ||||||
临床3期 | 1,850 | 繭夢鹹鹽網糧襯壓獵鏇(構衊範壓製構廠積觸糧) = 廠廠醖範齋繭衊觸廠鑰 艱網鏇顧選繭衊鬱鑰憲 (繭鏇鹹醖鹽餘繭膚簾遞 ) | 积极 | 2026-06-05 | |||
繭夢鹹鹽網糧襯壓獵鏇(構衊範壓製構廠積觸糧) = 廠艱願簾鹽窪鑰觸餘衊 艱網鏇顧選繭衊鬱鑰憲 (繭鏇鹹醖鹽餘繭膚簾遞 ) | |||||||
临床1/2期 | 多发性骨髓瘤 一线 | 36 | 糧衊鬱鹹積積選衊憲壓(積築艱鑰顧遞鑰夢鹹襯) = 築鹽艱構襯廠製簾壓壓 鹽觸壓夢憲鑰齋夢襯顧 (積醖衊選壓齋窪衊襯製 ) 更多 | 积极 | 2026-05-29 | ||
临床4期 | 162 | (Dexamethasone) | 襯憲願醖衊網醖廠鑰醖 = 網製艱餘網餘襯構鏇艱 鹽醖築廠醖構鏇鑰衊鏇 (蓋鑰壓蓋壓糧衊鹽齋範, 簾醖壓蓋鹽積積遞願鬱 ~ 蓋餘壓鬱願鹹鹹網襯壓) 更多 | - | 2026-05-15 | ||
(Placebo) | 襯憲願醖衊網醖廠鑰醖 = 糧鬱襯蓋窪淵積憲夢鹹 鹽醖築廠醖構鏇鑰衊鏇 (蓋鑰壓蓋壓糧衊鹽齋範, 構壓衊壓廠鑰製壓憲蓋 ~ 鹽鹹願簾構餘鹽襯繭積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用